{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:25:54Z","timestamp":1740108354978,"version":"3.37.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T00:00:00Z","timestamp":1543276800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s10096-018-3440-2","type":"journal-article","created":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T21:55:56Z","timestamp":1543355756000},"page":"409-412","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Iclaprim activity against wild-type and corresponding thymidine kinase\u2013deficient Staphylococcus aureus in a mouse protection model"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8228-7911","authenticated-orcid":false,"given":"David B.","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee Hyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy M.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,27]]},"reference":[{"key":"3440_CR1","doi-asserted-by":"crossref","unstructured":"Sader HS, Fritsche TR, Jones RN (2009) Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates. Antimicrob Agents Chemother 53:2171\u20135","DOI":"10.1128\/AAC.00129-09"},{"issue":"5","key":"3440_CR2","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1128\/AEM.22.5.812-817.1971","volume":"22","author":"AE Koch","year":"1971","unstructured":"Koch AE, Burchall JJ (1971) Reversal of the antimicrobial activity of trimethoprim by thymidine in commercially prepared media. Appl Microbiol 22(5):812\u2013817","journal-title":"Appl Microbiol"},{"key":"3440_CR3","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1016\/0006-2952(77)90271-4","volume":"26","author":"H Nottebrock","year":"1977","unstructured":"Nottebrock H, Then R (1977) Thymidine concentrations in serum and urine of different animal species and man. Biochem Pharmacol 26:2175\u20132179","journal-title":"Biochem Pharmacol"},{"key":"3440_CR4","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1016\/0006-2952(74)90272-X","volume":"23","author":"R Then","year":"1974","unstructured":"Then R, Angehrn P (1974) The biochemical basis of the antimicrobial action of sulfonamides and trimethoprim in vivo-I. Action of sulfonamides and trimethoprim in blood and urine. Biochem Pharmacol 23:2977\u20132982","journal-title":"Biochem Pharmacol"},{"key":"3440_CR5","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/0006-2952(75)90436-0","volume":"24","author":"R Then","year":"1975","unstructured":"Then R, Angehrn P (1975) The biochemical basis of the antimicrobial action of sulfonamides and trimethoprim in vivo-II. Experiments on the limited thymine and thymidine availability in blood and urine. Biochem Pharmacol 24:1003\u20131006","journal-title":"Biochem Pharmacol"},{"key":"3440_CR6","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"CLSI. M07-A11","year":"2018","unstructured":"CLSI. M07-A11 (2018) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, Tenth edn. Clinical and Laboratory Standards Institute, Wayne","edition":"Tenth"},{"key":"3440_CR7","volume-title":"Effect of thymidine on the activity of diaminopyrimidine antibacterial agents: generation and characterization of thmidine kinase-deficient Staphylococus auerius mutants","author":"A Haldimann","year":"2006","unstructured":"Haldimann A, Hawser S, Bihr M, Fels S, Rigo S, Weiss L, Islam K, Lociuro S (2006) Effect of thymidine on the activity of diaminopyrimidine antibacterial agents: generation and characterization of thmidine kinase-deficient Staphylococus auerius mutants. ICAAC, San Francisco"},{"key":"3440_CR8","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1128\/AAC.00325-09","volume":"53","author":"JM Entenza","year":"2009","unstructured":"Entenza JM, Haldimann A, Giddey M, Lociuro S, HAwser A, Morellion P (2009) Efficacy of iclaprim against wild-type and thymidine kinase-deficient methicillin-resistant Staphylococcus aureus isolates in an in vitro fibrin clot model. Antimicrob Agents Chemother 53:3635\u20133641","journal-title":"Antimicrob Agents Chemother"},{"key":"3440_CR9","unstructured":"National Research Council (2011) Guide for the care and use of laboratory animals, Eighth Edition. The National Academies Press, Washington"},{"key":"3440_CR10","doi-asserted-by":"crossref","unstructured":"Noviello S, Hawser S, Sader H, Huang DB (2018) In vitro activity of dihydrofolate reductase inhibitors and other antibiotics against gram-positive pathogens collected globally from 2004 to 2016. J Glob Antimicrob Resist, in press","DOI":"10.1016\/j.jgar.2018.10.018"},{"key":"3440_CR11","first-page":"e01184","volume":"62","author":"TP Lodise","year":"2018","unstructured":"Lodise TP, Bosso J, Kelly C, Williams PJ, Lane JR, Huang DB (2018) Pharmacokinetic and pharmacodynamic analyses to determine the optimal fixed dosing regimen of iclaprim for treatment of patients with serious infections caused by gram-positive pathogens. Antimicrob Agents Chemother 62:e01184\u2013e01117","journal-title":"Antimicrob Agents Chemother"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-018-3440-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-018-3440-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-018-3440-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T03:47:17Z","timestamp":1605498437000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-018-3440-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,27]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["3440"],"URL":"https:\/\/doi.org\/10.1007\/s10096-018-3440-2","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"type":"print","value":"0934-9723"},{"type":"electronic","value":"1435-4373"}],"subject":[],"published":{"date-parts":[[2018,11,27]]},"assertion":[{"value":"18 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"DBH is an employee of Motif BioSciences. TM is an employee of NeoSome Life Sciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research involved animals. All procedures in this research were in compliance with the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals, and the Office of Laboratory Animal Welfare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}